Accelrys and Agilent Technologies Enter Into Comprehensive Resale Agreement.

Agreement to Reduce Cost, Complexity for Customers by Automating Data-Analysis and Reporting Tools in Biology, Chemistry and QA/QC 

SAN DIEGO, Calif., & SANTA CLARA, Calif. -- Accelrys Inc. (NASDAQ: ACCL) and Agilent Technologies Inc. (NYSE: A) today announced they have entered into a comprehensive resale agreement to enable the licensing and integration of their informatics products. The partnership covers the breadth of informatics portfolios of both companies and will enable customers in the pharmaceutical industry to enjoy unprecedented integration of laboratory data, experimental results and insights across the enterprise.

"This partnership will enable unparalleled integration of informatics products," said Bruce von Herrmann, Agilent vice president and general manager, Informatics Division. "It will significantly benefit pharmaceutical companies that want to spend less time integrating existing informatics solutions and more time developing new, more effective medicines."

Agilent and Accelrys will offer compatible and enhanced solutions incorporating their respective portfolios of informatics products. Accelrys will resell OpenLAB Enterprise Content Manager, Kalabie Electronic Lab Notebook, and GeneSpring gene expression solutions. Agilent will resell Accord cheminformatics solutions and Pipeline Pilot Scientific Operating Platform solutions.

"Partnering with Agilent allows us to provide a broader range of scientific business-intelligence solutions to our pharmaceutical customers," said Mark J. Emkjer, president and chief executive officer, Accelrys. "We're enabling them to gain deeper insights and make more informed decisions from their scientific data across the research and development continuum. Agilent's strength in Laboratory Informatics, QA/QC and manufacturing are a natural complement to Accelrys' expertise in research, early development and scientific data management."

The combined solutions can be seen at the following events:

* the Agilent Worldwide Laboratory Informatics Conference in Berlin on Sept. 25-26;

* the ELNs - IQPC conference in Brussels on Sept. 26; and

* the Accord Informatics and Scitegic Pipeline Pilot user group meeting in Pistoia, Italy, Oct. 9-12.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.0 billion in fiscal 2006. Information about Agilent is available on the Web at www.agilent.com.

About Accelrys

Accelrys develops and commercializes Scientific Business Intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Our solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design as well as drug discovery and development. Our technology and services are designed to meet the needs of today's leading research and development organizations including leading commercial, government and academic organizations. For more information about Accelrys, visit its website at http://www.accelrys.com/.

Forward-Looking Statements 

This press release contains forward-looking statements. Such statements, including statements relating to the results of the partnership between Agilent and Accelrys, including statements relating to reducing cost of complexity for customers, product integration and benefits to the companies and their customers, are subject to risks and uncertainties including, but not limited to, the risks that the partnership will not result in such integration or other benefits, and that the companies' products will not be timely or successfully completed, developed or achieve market acceptance, demand relating to these products, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys and Agilent disclaim any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in their expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.